Bladder Cancer Reagents

Urothelial carcinoma (UC) has seen a therapeutic revolution with PD-1/PD-L1 checkpoint inhibitors, FGFR-targeted therapies, and ADCs (enfortumab vedotin, sacituzumab govitecan). abinScience provides validated antibodies, recombinant proteins, and biosimilar-grade reference proteins for the targets listed below. RUO

Key Biomarkers & Targets

PD-L1

CD274

Atezolizumab and pembrolizumab approved for UC. 130 products. Validated: Blocking, ELISA, FC, IF, IHC, WB.

Antibodies • Biosimilars • Proteins

FGFR3

Fibroblast Growth Factor Receptor 3

FGFR3 mutations/fusions in ~20% of UC; erdafitinib target. 20 products. Validated: ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

Nectin-4

PVRL4

ADC target of enfortumab vedotin in metastatic UC. 29 products. Validated: ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

TROP2

TACSTD2

ADC target for sacituzumab govitecan in UC. 32 products. Validated: ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

HER2

ErbB2

HER2 overexpression in ~10–15% of UC; T-DXd showing activity. 115 products. Validated: Blocking, ELISA, FC, IF, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

B7-H3 / CD276

Immune Checkpoint

Overexpressed in UC; emerging ADC and checkpoint target. 39 products. Validated: ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

GATA3

Urothelial Lineage Marker

Used for UC lineage confirmation in differential diagnosis. 6 products. Validated: FC.

Antibodies • Proteins

EGFR

ErbB1

EGFR pathway in urothelial carcinoma. 108 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

Why Researchers Choose abinScience

IHC-Validated AntibodiesAntibodies with IHC validation available for: PD-L1, FGFR3, Nectin-4, TROP2, HER2, B7-H3. See individual product pages for clone details and recommended dilutions.

Flow Cytometry ReadyFC-validated antibodies available for: PD-L1, FGFR3, Nectin-4, TROP2, HER2, B7-H3. Multiple conjugates (FITC, APC, PE, PerCP) offered for select clones.

Research-Grade BiosimilarsBiosimilar-grade reference proteins with ELISA and FACS validation for: PD-L1, FGFR3, Nectin-4, TROP2, HER2.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

IHC-based biomarker detection: We offer IHC-validated antibodies for PD-L1, FGFR3, Nectin-4, TROP2, HER2. See product pages for validated species and recommended dilutions.
Flow cytometry immunophenotyping: FC-validated antibodies available for PD-L1, FGFR3, Nectin-4, TROP2, HER2. Select clones offered in FITC, APC, PE, and PerCP conjugates.
Functional and blocking assays: Antibodies with blocking/neutralization validation available for: PD-L1, HER2, EGFR.
Biosimilar comparability: Research-grade biosimilar proteins (ELISA/FACS/Functional assay validated) available for PD-L1, FGFR3, Nectin-4, TROP2.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

What PD-L1 reagents do you offer?

We offer 58 detection antibodies, 59 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IF, IHC, WB. Available clones include: 22C3 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), SP142 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Envafolimab, Pacmilimab, Cosibelimab).

What HER2 reagents do you offer?

We offer 33 detection antibodies, 75 research-grade biosimilar proteins, and 7 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IF, IHC, SPR, WB. Available clones include: A21 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), 1A064 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Disitamab, Timigutuzumab, Gancotamab).

What EGFR reagents do you offer?

We offer 45 detection antibodies, 49 research-grade biosimilar proteins, and 14 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: SAA2220 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), 11F8 (ELISA, FC, WB; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Modotuximab, Tomuzotuximab, Depatuxizumab).

What B7-H3 / CD276 reagents do you offer?

We offer 25 detection antibodies, 8 research-grade biosimilar proteins, and 6 recombinant proteins. Validated applications include: ELISA, FC, IHC, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), Mab 8H9 (FC; APC, FITC, PE), SAA0090 (FC; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Enoblituzumab, Omburtamab, Mirzotamab).

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.